Marianne Davies on Managing Immunotherapy Side Effects in Lung Cancer

Marianne Davies, NP
Published: Monday, Nov 02, 2015



Marianne Davies, NP, Assistant Professor of and Clinical Instructor in Nursing, Yale Cancer Center, discusses immune-mediated adverse events in lung cancer.

With the use of immunotherapies in lung cancer becoming increasingly common, it is important to understand how to manage the side effects associated with these treatments, says Davies.

The key to management is early detection. If a patient develops a grade 1 toxicity associated with a checkpoint inhibitor, oftentimes delaying treatment is an effective management strategy, says Davies. Patients can then successfully go on to continue their therapy once the side effect is resolved.

The standard treatment of choice for the management of immune-mediated adverse events is steroids, explains Davies. Side effects can impact any organ system, causing inflammation. In lung cancer, a particularly concerning immunotherapy side effect is pneumonitis, or inflammation of the lungs.



Marianne Davies, NP, Assistant Professor of and Clinical Instructor in Nursing, Yale Cancer Center, discusses immune-mediated adverse events in lung cancer.

With the use of immunotherapies in lung cancer becoming increasingly common, it is important to understand how to manage the side effects associated with these treatments, says Davies.

The key to management is early detection. If a patient develops a grade 1 toxicity associated with a checkpoint inhibitor, oftentimes delaying treatment is an effective management strategy, says Davies. Patients can then successfully go on to continue their therapy once the side effect is resolved.

The standard treatment of choice for the management of immune-mediated adverse events is steroids, explains Davies. Side effects can impact any organ system, causing inflammation. In lung cancer, a particularly concerning immunotherapy side effect is pneumonitis, or inflammation of the lungs.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x